2006 issue 2

Back

Volume 22, issue 2

Original article

Prophylactic efficacy of lithium in patients with bipolar affective disorder and polymorphisms of dopamine receptors genes type D2

Aleksandra Suwalska1, Janusz Rybakowski1, Monika Dmitrzak-Węglarz2, Piotr Czerski2, Maria Skibińska2, Anna Leszczyńska-Rodziewicz1, Agnieszka Permoda-Osip1, Joanna Hauser1,2
1. Klinika Psychiatrii Dorosłych Akademii Medycznej w Poznaniu
2. Pracownia Genetyki Psychiatrycznej Akademii Medycznej w Poznaniu
Farmakoterapia w Psychiatrii i Neurologii, 2006, 2, 79–85
Keywords: bipolar affective illness, lithium carbonate, dopamine receptors DRD2, DRD3, DRD4

Abstract

Objectives: the present study was aimed to investigate possible associations between polymorphisms of dopamine receptors genes type D2 (DRD2, DRD3 and DRD4) and prophylactic efficacy of lithium treatment in patients with bipolar affective disorder.
Material and methods: ninety two patients (54 female, 38 male) diagnosed with bipolar affective disorder. Mean duration of lithium treatment was 14,6±7,5 years (range 5-32 years), and lithium dosage was adjusted to maintain lithium level in the range 0.5-0.8 mmol/l. Patients were divided into three subgroups based on lithium efficacy: excellent lithium responders (n=23), partial responders (n=47) and non-responders (n=22).
Results: no association between studied polymorphisms of dopamine receptors genes DRD2, DRD3, DRD3 and lithium efficacy was found in our group of patients with bipolar affective disorder.

Address for correspondence:
Aleksandra Suwalska
Klinika Psychiatrii Dorosłych Akademii Medycznej
ul. Szpitalna 27/33, 60-572 Poznań
tel. (061) 8475087, fax. (061) 8480392
E-mail autora korespondującego: asuwalska@amp.edu.pl